Vaxart, Inc.

    Jurisdiction
    United States
    ISIN
    US92243A2006 (VXRT)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €69.55M
    Gross margin
    100.0%
    EBIT
    -€47.82M
    EBIT margin
    -68.8%
    Net income
    -€48.80M
    Net margin
    -70.2%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €97.36M +40.0% -€91.50M +87.5%
    N/A -€194.45M +112.5%
    N/A -€199.79M +2.7%

    Dividends

    Last dividend amount
    $1.11
    Ex date

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Finney Kevin N/A +167K $0.37 +$61.67K
    Watson W. Mark N/A +10K $0.41 +$4.10K

    Earnings Calls

    Latest earnings call: August 13, 2025

    Add to watchlist

    Notifications